In the following video, Motley Fool health-care analyst David Williamson brings investors up to speed on the patent battle between Gilead (GILD +0.17%) and Idenix (NASDAQ: IDIX) over the next generation of drugs to treat hepatitis C, one of the hottest spaces in health care today based on some incredible recent successes. David tells investors how Gilead may have won this particular round of the battle and what the war could mean for both companies down the road.
Gilead wins the round, but the war continues.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid